2025 Oklahoma Thoracic Oncology Conference

Oklahoma City, OK US
March 21, 2025

This CME-accredited activity, the 2025 Oklahoma Thoracic Oncology Conference, brings together leaders in the field of thoracic oncology to provide an extensive overview of both current and emerging strategies for managing lung cancer (NSCLC and SCLC). The primary aim of this conference is to enhance the knowledge and competence of participants, enabling them to apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for lung cancer patients. The program includes detailed discussions and analyses of the latest scientific discoveries and advancements in molecular testing and targeted therapies for thoracic oncology. The expert faculty will focus on the clinical application of diagnostics, biomarkers, and various therapeutic agents, discussing how these tests and treatments can be effectively used to improve patient care.

Target Audience

  • Medical Oncologists
  • Surgeons
  • Radiation Oncologists
  • Pathologists
  • Oncology Fellows
  • Oncology Nurses
  • Nurse Practitioners
  • Physician Assistants
  • Pharmacists

Organizing Committee

Conference Director:

Binay Shah, MD, MHA - Binaytara Foundation

Conference Co-Chairs:

Raid Aljumaily, MD - OU Health

Abdul Rafeh Naqash MD - OU Health

Learning Objectives

At the conclusion of the activity, participants will be able to:

  1. Review the various actionable molecular abnormalities in lung cancer and learn about the appropriate testing and treatment strategies for these alterations.
  2. Summarize the efficacy and potential toxicities of immune checkpoint inhibitors, targeted therapies, and other chemotherapy agents in the management of lung cancer.
  3. Identify the role of perioperative systemic therapy options in curative-intent treatment of non-small cell lung cancer (NSCLC), including chemotherapy, immune checkpoint inhibitors, and targeted therapies.
  4. Apply practice-changing clinical data and expert recommendations to optimize clinical outcomes for patients with lung cancer.

You may also be interested in

Dogmas and Controversies in Hematologic Malignancies: Los Angeles

Dogmas and Controversies in Hematologic Malignancies: Los Angeles is an annual 2-day CME-accredited conference featuring leading experts who will deliver a comprehensive review of current and emerging strategies for managing Hodgkin and non-Hodgkin lymphoma, chronic lymphocytic l
Course summary
Available credit: 
  • 6.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.00 Contact Hours.
Course opens: 
10/30/2024
Course expires: 
03/21/2025
Event starts: 
03/21/2025 - 8:00am PDT
Event ends: 
03/21/2025 - 4:30pm PDT
Cost:
$350.00
Add to calendar: 

March 21st, 2025

All times are listed in Central Daylight Time (CDT)

07:00 AM – 07:30 AM  Registration, Breakfast, & Exhibits

07:30 AM – 08:00 AM   Binaytara Foundation's Efforts in Improving Cancer Care Disparities - Binay Shah, MD, MHA

08:00 AM – 09:00 AM  Session 1 - Pathology, Genetics, and Biomarkers

Session Chair: 

08:00 AM – 08:15 AM  Pathological Classification of Thoracic Tumors -

08:15 AM – 08:30 AM  Germline Testing and Lung Cancer -

08:30 AM – 08:45 AM  Genomics and Biomarkers: Thoracic Oncology in 2024 -

08:45 AM – 09:00 AM  Panel Discussion -

09:00 AM – 09:45 AM  Break & Exhibits

09:45 AM – 10:25 AM  Session 2 - Controversies in Thoracic Oncology

Session Chair: 

Debate: Locally Advanced NSCLC: Is Surgery the New Standard of Care?

09:45 AM – 10:00 AM  Yes - 

10:00 AM – 10:15 AM  No - 

10:15 AM – 10:25 AM  Panel Discussion -

10:25 AM – 11:05 AM  Session 3 - Understanding and Managing Pneumonitis from Immune Checkpoint Inhibitors and Novel Anticancer Therapies

Session Chair: 

10:25 AM – 10:40 AM  ADC Lung Toxicities: The Knowns and Unknowns and Where Do We Stand -

10:40 AM – 10:55 AM  MultiD Care ICI Pneumonitis and Emerging Therapeutic Approaches -

10:55 AM – 11:05 AM  Panel Discussion -

11:05 AM – 12:20 PM  Session 4 - Frontline Therapy in Lung Cancer

Session Chair: 

Debate: Frontline Therapy in Lung Cancer - EGFR

11:05 AM – 11:20 AM  More is Better - 

11:20 AM – 11:35 AM  More is NOT Better -

Debate: Frontline Therapy in Lung Cancer - EGFR

11:35 AM – 11:50 AM  More is Better: Dual Immune Checkpoint Inhibition and Quad Regimens -

11:50 AM – 12:05 PM  More is NOT Better: Triplet and Single Agent IO is the Standard -

12:05 PM – 12:20 PM  Panel Discussion -

12:20 PM – 01:20 PM  Lunch & Exhibits

01:20 PM – 02:20 PM  Session 5 - Current Standards and Emerging Therapies

Session Chair: 

01:20 PM –  01:35 PM  NSCLC: Immunotherapy -

01:35 PM – 01:50 PM  NSCLC: Immunotherapy -

01:50 PM – 02:05 PM  Small Cell -

02:05 PM – 02:20 PM  Panel Discussion -

02:20 PM – 02:40 PM  Break & Exhibits

02:40 PM – 04:10 PM  Session 6 - Rapid Reviews

Session Chair: 

02:40 PM –  02:55 PM  How I Approach Peri-Operative Therapy -

02:55 PM – 03:10 PM  ADCs: Hope or Hype? -

03:10 PM – 03:25 PM  ALK, HER2, ROS, RET, and MET in 2024 -

03:25 PM – 03:40 PM  Post -Targeted Therapy Landscape in NSCLC -

03:40 PM – 03:55 PM  How I Approach Oligometastatic Disease -

03:55 PM – 04:10 PM  Panel Discussion -

04:10 PM  Adjourn

Embassy Suites by Hilton Oklahoma City Downtown Medical Center
741 N Phillips Ave
Oklahoma City, OK 73104
United States

HOTEL INFORMATION 

Coming Soon ..

FACULTY INFORMATION COMING SOON

 

Available Credit

  • 6.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 6.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 6.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 6.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 6.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 6.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 6.00 Contact Hours.

If you are interested in exhibiting at this meeting, please visit our exhibit page here - https://education.binayfoundation.org/exhibit-information

 

Price

Cost:
$350.00
Please login or register to take this course.

POLICY ON INDUSTRY EMPLOYEE'S PARTICIPATION IN MARKETING/EDUCATION ACTIVITY AT THE CONFERENCE: 

All marketing and product promotion activities must occur in the designated exhibit hall or product theater space separate from the area where this accredited continuing education takes place. 

The exhibit and product promotion space is reserved only for companies that have purchased marketing and product promotion slots at the conference.  The individual registration fee doesn't include marketing or product theater privileges. Please refer to the sponsorship handbook for the types of marketing activities included in your display/sponsorship fees. 

If your company has NOT purchased a marketing opportunity such as an exhibit table, product theater slot or another type of marketing opportunity, you may not participate in any marketing activity or attempt to educate healthcare providers about your product or service. Industry attendees of companies without marketing opportunities must refrain from interacting with healthcare providers at this meeting in any form, including introducing themselves as an employee of the company, discussing the care of patients, handing out flyers and brochures, inviting participants to the company's other programs, etc.

Violating this policy will result in a fine equivalent to a general display fee for that conference. 

 

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 
  • If your company has NOT purchased a display table at the event AND you attended the meeting paying a full industry registration fee, BUT YOU PARTICIPATED IN MARKETING AND PROMOTIONAL ACTIVITIES, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

CANCELLATION POLICY

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is canceled six weeks before the conference.
  • No refunds will be issued if registration is canceled after that date.  

No credits will be offered if you do not complete all required steps of this activity, including registration and participation in the live meeting.